BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 19, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2012

View Archived Issues

Novel shRNA molecule demonstrates potential efficacy for patients with mesothelioma

Read More

Enrollment commences in new phase II study of ELND-005

Read More

TAS-114 demonstrates promising antitumor activity in combination with other oncolytic agents

Read More

Selecta Biosciences and Sanofi sign global collaboration to develop allergy immunotherapies

Read More

AiCuris begins second trial of pritelivir for genital herpes

Read More

GW Pharmaceuticals identifies novel oral cannabinoid candidate for type 2 diabetes

Read More

Novel, orally bioavailable HSP 90 inhibitor developed by Taiho for cancer

Read More

Phase I and II data reveal efficacy of AMG-145

Read More

Linaclotide receives European marketing approval for IBS-C

Read More

New APE-1 inhibitors presented by U.S. Department of Health & Human Services

Read More

Usher III Initiative prepares novel compounds for Usher syndrome

Read More

Polish group designs novel agents for HCMV infection

Read More

Researchers at Merck & Co. disclose new B-raf inhibitors

Read More

APY-0201 significantly ameliorates skin inflammation in animal models of psoriasis

Read More

ElexoPharm and Merck & Co. cooperate on novel series of CYP11B2 inhibitors

Read More

FDA accepts tivozanib NDA filing

Read More

Safety and pharmacokinetic phase I data reported for MGL-3196

Read More

NovImmune begins phase I study of NI-0101

Read More

NICE recommends Bronchitol for adults with cystic fibrosis

Read More

Mochida Pharmaceutical patents new GRP40 receptor agonists

Read More

Novel heat shock protein HSP 90 inhibitor prodrugs prepared at Myrexis

Read More

NICE recommends ivabradine for patients with chronic heart failure

Read More

Coronado Biosciences begins phase I/II trial of CNDO-109

Read More

NPS licenses rights to teduglutide in Israel to Neopharm

Read More

First clinical data on RG-7212 show target modulation and signs of efficacy

Read More

Biotron begins extended preclinical toxicology studies of BIT-225

Read More

FDA committee recommends accelerated approval of bedaquiline NDA

Read More

Kowa and Sanwa Kagaku Kenkyusho set to launch Suiny in Japan

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Rare disease illustration

    Rare earth: Biomarin to use global reach post-$4.8B Amicus buy

    BioWorld
    Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing